Real-life Efficacy of Insulia® Tool in Patients Living with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)

Effectiveness in Real Life of the Insulia® Digital Tool in Patients with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05331339

Acronym

INSULIA

Enrollment

Registered

2022-04-15

Start date

2022-11-02

Completion date

2022-12-02

Last updated

2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a single-center study. The assumption is that a better metabolic control with this tool.

Detailed description

Basal insulin titration in people with type 2 diabetes is of major importance to obtain the optimal dose to regulate fasting blood glucose without hypoglycemia. Significant inertia in treatment optimization has been observed among both general practitioners and diabetologists. The INSULIA tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) has been supported by the health authorities. The data collected are of a single-center cohort of adult patients with type 2 diabetes who used this tool between 2018 and 2021. It is supposed that a better metabolic control with this tool and aimed to understand factors associated with better results.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years old. * Patients with type 2 diabetes. * Initiation or adjustment of basal insulin. * Prescription of Insulia® for more than 6 months (between august 2018 and june 2021) * Informed patient not opposed to the research

Exclusion criteria

Patient opposed to the research

Design outcomes

Primary

Measure	Time frame	Description
HbA1c	at 6 months	Evolution of HbA1c between baseline and 6 months after Insulia initiation

Secondary

Measure	Time frame	Description
Insulin	at 6 months	Evolution of daily dose of basal insulin between baseline and 6 months after Insulia initiation
HbA1c objective	at 6 months	Percentage of patients reaching the HbA1c target after 6 months
Mean fasting glucose	at 6 months	Percentage of patients reaching a mean fasting glucose \< 150 mg/dL for 7 days after 6 months

Countries

France

Outcome results